124 related articles for article (PubMed ID: 38194487)
1. Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy?
Flores JM; Vertosick E; Jenkins LC; Cooper J; Benfante N; Sjoberg D; Vickers AJ; Eastham JA; Laudone VP; Scardino PT; Nelson CJ; Mulhall JP
J Urol; 2024 Mar; 211(3):400-406. PubMed ID: 38194487
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
Loeb S; Folkvaljon Y; Robinson D; Schlomm T; Garmo H; Stattin P
Eur Urol; 2016 Nov; 70(5):824-828. PubMed ID: 26743040
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Phosphodiesterase 5 Inhibitor on Biochemical Recurrence Following Radical Prostatectomy in Patients with Prostate Cancer.
Chung JW; Kim JW; Ha YS; Choi SH; Lee JN; Kim BS; Kim HT; Yoo ES; Kwon TG; Kim TH
Urol J; 2019 Jun; 16(3):255-259. PubMed ID: 31204438
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase Type 5 Inhibitor Use Following Radical Prostatectomy is not Associated with an Increased Risk of Biochemical Recurrence.
Jo JK; Kim K; Lee SE; Lee JK; Byun SS; Hong SK
Ann Surg Oncol; 2016 May; 23(5):1760-7. PubMed ID: 26717939
[TBL] [Abstract][Full Text] [Related]
5. Is there a relationship between phosphodiesterase type 5 inhibitors and biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis.
He Q; Liao BH; Xiao KW; Zhou L; Feng SJ; Li H; Wang KJ
Int Urol Nephrol; 2018 Dec; 50(12):2113-2121. PubMed ID: 30232722
[TBL] [Abstract][Full Text] [Related]
6. Penile rehabilitation for postprostatectomy erectile dysfunction.
Philippou YA; Jung JH; Steggall MJ; O'Driscoll ST; Bakker CJ; Bodie JA; Dahm P
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012414. PubMed ID: 30352488
[TBL] [Abstract][Full Text] [Related]
7. A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy.
Gallina A; Bianchi M; Gandaglia G; Cucchiara V; Suardi N; Montorsi F; Briganti A
Eur Urol; 2015 Nov; 68(5):750-3. PubMed ID: 25700565
[TBL] [Abstract][Full Text] [Related]
8. Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review.
Aoun F; Slaoui A; Walid AHO; Albisinni S; Assenmacher G; de Plaen E; Azzo JM; Peltier A; Roumeguère T
Prog Urol; 2018 Oct; 28(12):560-566. PubMed ID: 30201551
[TBL] [Abstract][Full Text] [Related]
9. Sexual Rehabilitation After Nerve-Sparing Radical Prostatectomy: Free-of-Charge Phosphodiesterase Type 5 Inhibitor Administration Improves Compliance to Treatment.
Siena G; Mari A; Canale A; Mondaini N; Chindemi A; Greco I; Saleh O; Serni S; Nicita G; Minervini A; Carini M
J Sex Med; 2018 Feb; 15(2):120-123. PubMed ID: 29425663
[TBL] [Abstract][Full Text] [Related]
10. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
11. Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer.
Song C; Park S; Park J; Shim M; Kim A; Jeong IG; Hong JH; Kim CS; Ahn H
Prostate; 2015 Feb; 75(2):211-7. PubMed ID: 25327522
[TBL] [Abstract][Full Text] [Related]
12. Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database.
Ho T; Gerber L; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
Eur Urol; 2012 Nov; 62(5):910-6. PubMed ID: 22921964
[TBL] [Abstract][Full Text] [Related]
13. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy.
Briganti A; Karnes RJ; Joniau S; Boorjian SA; Cozzarini C; Gandaglia G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Sun M; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
Eur Urol; 2014 Sep; 66(3):479-86. PubMed ID: 24345725
[TBL] [Abstract][Full Text] [Related]
14. Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen.
Greenberg SA; Washington SL; Lonergan PE; Cowan JE; Baskin AS; Nguyen HG; Odisho AY; Simko JP; Carroll PR
J Urol; 2021 Sep; 206(3):706-714. PubMed ID: 33905262
[TBL] [Abstract][Full Text] [Related]
15. Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer.
Hamada R; Nakashima J; Ohori M; Ohno Y; Komori O; Yoshioka K; Tachibana M
Int J Clin Oncol; 2016 Jun; 21(3):595-600. PubMed ID: 26585896
[TBL] [Abstract][Full Text] [Related]
16. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
Freedland SJ; Vidal AC; Howard LE; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ;
Cancer; 2017 Nov; 123(21):4199-4206. PubMed ID: 28654204
[TBL] [Abstract][Full Text] [Related]
17. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Allott EH; Howard LE; Cooperberg MR; Kane CJ; Aronson WJ; Terris MK; Amling CL; Freedland SJ
BJU Int; 2014 Nov; 114(5):661-6. PubMed ID: 24588774
[TBL] [Abstract][Full Text] [Related]
18. Prediction of biochemical recurrence after laparoscopic radical prostatectomy.
Bejrananda T; Pliensiri P
BMC Urol; 2023 Nov; 23(1):183. PubMed ID: 37953250
[TBL] [Abstract][Full Text] [Related]
19. Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence.
Pompe RS; Gild P; Karakiewicz PI; Bock LP; Schlomm T; Steuber T; Graefen M; Huland H; Tian Z; Tilki D
Prostate; 2018 Jun; 78(9):676-681. PubMed ID: 29570821
[TBL] [Abstract][Full Text] [Related]
20. Let's rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy.
Kim SJ; Kim JH; Chang HK; Kim KH
J Exerc Rehabil; 2016 Jun; 12(3):143-7. PubMed ID: 27419107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
